evolcSign inStart free
Menu

Elasmogen

Biopharma developing ELN28, a dual-acting TNFα and JAK inhibitor conjugate for hidradenitis suppurativa patients

Foresterhill, United KingdomFounded 2014elasmogen.comWebsite technologies

+ Add to sales board

Highlights

  • New on EvolcAdded 2026-10-28

About Elasmogen

Elasmogen is a privately held biopharmaceutical company that discovers and develops biologics for immune-mediated inflammatory disease. Its lead asset, ELN28, is a first-in-class, dual-acting soloMER conjugate that combines TNFα blockade with localised JAK inhibition, built on what the company describes as an ADC-inspired approach.

The company targets hidradenitis suppurativa, a chronic inflammatory skin condition, and is working to advance ELN28 clinically. Its investors are Deepbridge Capital LLP, BGF, the Scottish National Investment Bank and Scottish Enterprise. Its leadership team is headed by founder and CEO Professor Caroline Barelle.

Elasmogen was founded in 2014 and is headquartered in Foresterhill, United Kingdom.

Product: ELN28, a first-in-class dual-acting soloMER conjugate combining TNFα blockade and localised JAK inhibition for hidradenitis suppurativa.

Jobs at Elasmogen

No open positions listed right now.

More biotech & pharma companies

  • Eleventx

    Extended-release RNA medicines for chronic disease, starting in cardiometabolic, developed with pharma partners
    Cambridge, United KingdomBiotech & pharma2 open jobs

  • Enara Bio

    Cancer immunotherapies for patients with solid tumors, developed using dark-antigen discovery and T-cell engager platforms
    Oxford, United KingdomBiotech & pharmaFounded 2016
    New on Evolc

  • Ensocell

    AI-driven discovery of precision therapies for fibrotic and autoimmune diseases using human biological data
    United KingdomBiotech & pharma1 open job
    New on Evolc

  • Enterobiotix

    Clinical-stage microbiome therapeutics developing the oral drug EBX-102-02 for irritable bowel syndrome and related gut and liver diseases
    Bellshill, United KingdomBiotech & pharmaFounded 2017
    New on Evolc

  • Enterprise Therapeutics

    Develops investigational medicines for people with cystic fibrosis and other respiratory diseases
    Brighton, United KingdomBiotech & pharmaFounded 2014
    New on Evolc

  • Epidarex Exeed

    Seeds early-stage life science ventures by developing breakthrough therapeutic research into investable assets
    Edinburgh, United KingdomBiotech & pharmaFounded 2019
    New on Evolc

All biotech & pharma companies →

Website technologies

Older, unverified list. Detection dates and supporting evidence are not yet available.

  • Google reCAPTCHA
  • LiteSpeed
  • WooCommerce
  • WordPress
  • jQuery